Showing results (91-100 of 125) with videos related to
Sort By:
Pageof 13
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2014
Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancerChau Dang, Neil Iyengar, Farrah Datko, et al.The AAPS Journal|June 17, 2017
Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance)Shailly Mehrotra, Manish R Sharma, Elizabeth Gray, et al.Breast Cancer Research and Treatment|March 17, 2006
Effect of adjuvant breast cancer chemotherapy on cognitive function from the older patient's perspectiveArti Hurria, Shari Goldfarb, Carol Rosen, et al.Journal of Clinical Pharmacology|December 6, 2019
Personalized Management of Chemotherapy-Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance)Manish R Sharma, Shailly Mehrotra, Elizabeth Gray, et al.Breast Cancer Research and Treatment|March 12, 2017
Using ePrognosis to estimate 2-year all-cause mortality in older women with breast cancer: Cancer and Leukemia Group B (CALGB) 49907 and 369901 (Alliance A151503)Gretchen G Kimmick, Brittny Major, Jonathan Clapp, et al.Proceedings of the National Academy of Sciences of the United States of America|February 16, 2011
Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patientsMaurizio Scaltriti, Pieter J Eichhorn, Javier Cortés, et al.The New England Journal of Medicine|September 3, 2004
Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancerKevin S Hughes, Lauren A Schnaper, Donald Berry, et al.Cancer Research|November 4, 2005
HER2/neu-induced mammary tumorigenesis and angiogenesis are reduced in cyclooxygenase-2 knockout miceLouise R Howe, Sung-Hee Chang, Kelly C Tolle, et al.Clinical Breast Cancer|December 15, 2010
Dose dense cyclophosphamide, methotrexate, fluorouracil is feasible at 14-day intervals: a pilot study of every-14-day dosing as adjuvant therapy for breast cancerPamela Drullinsky, Steven M Sugarman, Monica N Fornier, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 8, 2008
The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancerChau Dang, Monica Fornier, Steven Sugarman, et al.Pageof 13